Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Tang WH, Brennan D, McErlean E, Hazen SL, Topol EJ. Bhatt DL, et al. Among authors: blankenship jc. Am Heart J. 2007 Jul;154(1):137-43. doi: 10.1016/j.ahj.2007.03.029. Am Heart J. 2007. PMID: 17584566 Clinical Trial.
Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ. Lefkovits J, et al. Among authors: blankenship jc. J Am Coll Cardiol. 1996 Oct;28(4):849-55. doi: 10.1016/s0735-1097(96)00239-2. J Am Coll Cardiol. 1996. PMID: 8837559 Free article. Clinical Trial.
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Gutierrez JA, Harrington RA, Blankenship JC, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Généreux P, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Gutierrez JA, et al. Among authors: blankenship jc. Eur Heart J. 2016 Apr 7;37(14):1122-30. doi: 10.1093/eurheartj/ehv498. Epub 2015 Sep 23. Eur Heart J. 2016. PMID: 26400827 Free PMC article. Clinical Trial.
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, White J, Topol EJ. Ross MJ, et al. Among authors: blankenship jc. J Am Coll Cardiol. 2003 Sep 17;42(6):981-8. doi: 10.1016/s0735-1097(03)00913-6. J Am Coll Cardiol. 2003. PMID: 13678916 Free article. Clinical Trial.
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Mandak JS, et al. Among authors: blankenship jc. J Am Coll Cardiol. 1998 Jun;31(7):1518-24. doi: 10.1016/s0735-1097(98)00130-2. J Am Coll Cardiol. 1998. PMID: 9626829 Free article. Clinical Trial.
257 results